Gary Kelley (Chairman of the Board, President & Chief Executive Officer)
Paul Smith (Executive Vice President & Chief Financial Officer)
PRESS ARCHIVE
2004-10-12 - Biogenerics Purchases Interest in North
2004-09-27 - Biogenerics Limited welcomes Paul Smith
2004-08-25 - Biogenerics Limited and Mariners Choice
2004-10-12 - Biogenerics Purchases Interest in North
TORONTO, ONTARIO October 13, 2004 Biogenerics Limited, (NASDAQ PKS: BIGN) is pleased to announce that it has made an investment in 2018251 Ontario Inc., a holding company with significant oil and gas reserves in Ontario, Canada. As part of the longer-term investment plan, Biogenerics intends to purchase a greater interest in 2018251 Ontario Inc., with a first right of refusal, in the productive acreage owned by 2018251 Ontario Inc.
2018251 Ontario Inc. owns several thousand gross acres of off-shore crown land near Romney Township in Kent County and also in the Dover field in Lambton County, Ontario. One of the more important assets of 2018251 Ontario Inc. is an over-riding royalty interest in a five-kilometer long horizontal well in Romney, Ontario, which is the longest horizontal well in North America, and also the recently drilled lateral to this well.
"The existing infrastructure of 2018251 Ontario Inc. offers a unique opportunity for us to complement our existing oil and gas interests in the world, while optimizing the value of our North American interests," said Gary Kelley, President and Chief Executive Officer. "We hope that our long-term investment in this company will lead to other investments in Ontario and especially into investments in new oil and gas recovery technologies like horizontal drilling."
NEED FUNDING PARTNER WITH BIOGENERICS
A company can be created based on ideas, but it's built on management, vision and execution. With their team's depth of experience in strategic planning, team-building, acquisitions, negotiation, operations and financing, they'll work with you on the big picture, so your team can focus more on critical day-to-day operations.
They're not passive partners, nor are they invasive. Their strategic partners attest to their success in building great relationships.
Beginning with a great idea, a sense of chemistry and a congruence of goals, together they're company builders, committed to sustainability over the long term.
Some great ideas just happen. Great companies never do.
They invest in two things: People and true Intellectual Property. With these two components in place, they can help you build your company.
They make decisions quickly and act on them quickly.
When they receive a business plan, they review it, and if they share your vision, they'll contact you to arrange a meeting to discuss the plan in detail and get to know each of your team members. If they reach a sense of business and personal synergy over a few meetings, they'll discuss the terms of investment, and produce a draft term sheet. They like simple structures that are fair to all parties concerned.
They then perform due diligence, evaluating the market, the products or services, the competition and the strategy, in order to develop an in-depth understanding of the business dynamics. They'll check references, and talk to customers and other industry sources.
In parallel with due diligence, they'll start the legal process, and unless significant problems arise, they'll finalize the terms of investment - often within 30 to 60 days of our first meeting.
They want to be the first professional money to invest in your company, and typically take a 20-40% equity stake. This gives them significant influence, but not control, in the company. They usually want a seat on the Board, and full access to company records and information. They're non-invasive, but they're not passive money partners. A good sense of chemistry between Biogenerics and their prospective investees is a crucial factor in whether or not they become partners.
-----------------------------------------------------------------
Disclaimer
This profile published by OTC Live, Inc is an independent electronic publication providing information and factual analysis on selected companies. All statements and expressions are the opinion of OTC Live, Inc and are not meant to be either investment advice or a solicitation or recommendation to buy, sell, or hold securities. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. OTC Live, Inc is not a registered investment advisor or a broker dealer. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Profiles rely on information provided by the featured Companies and/or Edgar filings. While OTC Live, Inc believes its sources to be reliable, associates of OTC Live, Inc,
or any affiliated parties make no representation or warranty as to the accuracy of the information provided. Readers should not rely solely on the information contained in this publication, but should consult with their own independent tax, business and financial advisors with respect to any investment opportunity, including any contemplated investment in the advertised Company.
Factual statements in this publication are made as of the date stated and are subject to change without notice. OTC Live, Inc is not responsible for any claims made by the Company. We have prepared this report, drawing upon a range of public news, the company's website and information from sources in the industry, as well as data and opinions provided by the company. Prior to issuing this report, the Company reviewed and approved the contents in writing hereof. OTC Live, Inc has not independently verified the Company's representations. Any opinions expressed in this report are statements of judgment as of the date of publication. We urge readers to carefully verify all presentations within the report independently. The receipt of this publication shall not create, under any circumstances, any
implication that there has been no change in the affairs of the company profiled since the date of review. This advertisement does not provide an analysis of the Company's financial position. OTC Live, Inc of this advertisement has been compensated twenty thousand free trading registered shares by a third party for the preparation and electronic dissemination of this report and IR services. This should be viewed as a potential conflict of interest. Furthermore, associates of OTC Live, Inc may have stock positions on profiled companies from time to time. We may profit in the event the shares of the Company profiled by us increase in value. These positions may be liquidated from time to time even after we have made positive comments regarding the Company. The receipt of this information constitutes
your acceptance of these terms and conditions.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS: Except for historical information contained herein, the statements on this website and newsletter are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results in the future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition and risk inherent in the companies operations. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ``anticipate,'' ``estimate,'' ``expect,''
``project,'' ``intend,'' ``plan,", "anticipate", "guess", "think", "hear", "suggest", ``believe,'' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance.
As a suggestion, "Never, ever, make an investment based solely on what you read in an online newsletter or Internet bulletin board, especially if the investment involves a small, thinly-traded company that isn't well known," said Nancy M. Smith, Director of SEC's Office of Investor Education and Assistance. "Assume that the information about these companies is not trustworthy unless you can prove otherwise through your own independent research." "Internet Fraud" is available on the SEC's Web Site, at sec.gov.
Subscription Information
Follow the links below for subscription information. To be removed from future mailing, please click on the unsubscribe link.
Subscription Email: -i-shoot-spammers--subscr...@zinester.com
Subscription URL: zinester.com
Unsubscription Email: -i-shoot-spammers--unsubscr...@zinester.com
Unsubscription URL: zinester.com
------------------------------------------------------------------------------
From m28280.p-i-shoot-spammers--err...@ezinester.com Tue Oct 19 09:13:02 2004
Received: from shadow32.agava.net (shadow32.agava.net [198.173.4.8])
by send.it.helsinki.fi (8.12.11/8.12.11) with ESMTP id i9J6CuBq013608
for <-i-shoot-spammers->; Tue, 19 Oct 2004 09:12:58 +0300 (EEST)
Received: from localhost.localdomain (shadow32.agava.net [198.173.4.8])
by shadow32.agava.net (Postfix) with ESMTP id 56A116F41CF
for <-i-shoot-spammers->; Tue, 19 Oct 2004 02:12:49 -0400 (EDT)
Content-Type: text/plain; charset=iso-8859-1
Content-Transfer-Encoding: binary
MIME-Version: 1.0
X-Mailer: MIME-tools 5.411 (Entity 5.404)
Subject: BIGN on the RISE as oil hits $54
Date: Mon, 18 Oct 2004 17:50:40 -0400
X-MailList-Message-ID: 28280
List-Subscribe: <http://www.ezinester.com/mpb/ml_fs.cgi?Action=fs&topic=-i-shoot-spamm...>
Errors-To: m28280.p-i-shoot-spammers--err...@ezinester.com
List-Unsubscribe: <http://www.ezinester.com/mpb/unsub.cgi?-i-shoot-spammers-&-i-shoot-sp...>
Sender: "Zinester.com" <m28280.p-i-shoot-spammers--err...@ezinester.com>
List-Help: <http://www.ezinester.com>
List-Id: Zinester.com <-i-shoot-spammers-.zinester.com>
List-Post: NO
List-Owner: <mailto:otcp...@aol.com>
X-Zinester-PID: -i-shoot-spammers-
From: Stock Alerts <respo...@ezinester.com>
To: -i-shoot-spammers-
Reply-To: Stock Alerts <respo...@ezinester.com>
Message-Id: <20041019061249.56A116F4...@shadow32.agava.net>
Status: O
October 18, 2004
OTC: BIGN Biogenerics Limited
Recent Price: $0.275
KEY REASONS TO CONSIDER
Oil prices surged to a new record last week -- briefly above $54 a barrel for U.S. light crude -- on new violence in Iraq and reports that Russian oil giant Yukos might be forced to suspend sales, although its production was not interrupted. Both developments were seen as possibly disrupting production in an already tight world market for oil. This is why companies like Biogenerics Limited trading under the ticker symbol BIGN, could benefit significantly based on catalysts described above....
The company we are referring to is Biogenerics Limited Inc. (OTCBB: BIGN.pk ), which specializes in acquiring oil and gas leases that have potential for increased oil and natural gas production utilizing new technologies, well workovers and fracture stimulation systems.
With the price of oil setting new records, domestic oil production continues to weigh heavily on the minds of political pundits and financial analysts. As if $2 a gallon of gasoline hasn't been bad enough, people now should be bracing for sharply higher heating bills this winter whether they use oil or natural gas to warm their homes. In fact have you seen the earnings reports from the major oil/gas companies showing record revenues and billions in earnings? These big companies, flush with cash and hoping to keep prices high, are not going to be aggressively seeking exploration opportunities in our opinion. They are "fat, dumb and happy" at the moment. But with the bounty that high oil prices brings, smaller, independent producers are compelled into action - which brings us to a company we
feel could benefit significantly from current catalysts--.
WHY GET INVOLVED NOW?
Management believes for the next generation the entire world will still run on oil and natural gas. So far, alternative fuels are still too expensive to substitute for fossil fuels. Because of the unstable conditions in the Middle East , concerns about supply disruptions in Nigeria and Russian oil giant Yukos possible suspension of shipments to China next month, oil and gas markets will have a strong demand for the next few years. The United States is so dependent on foreign oil, the Company believes any new oil and gas reserves found in America will help the country be independent and not held hostage by the Arab oil producing nations and other external factors.
Biogenerics Limited, Inc., offers the opportunity for stock investors to be part of a company that has a vision to be a partner with the United States of America to become energy self-sufficient.
WHAT IS BIOGENERICS LIMITED
1. Their principle business is to fund emerging growth businesses with breakthrough proprietary products.
You're investing in a company that develops leading technologies through acquisitions.
2. Biogenerics interests are primarily in companies which have solid proprietary technology in Application
and Platform Software, Telecommunications and Fiber Optics Technologies and Biomedical Technology,
as well as other emerging technology and environmentally sensitive product areas.
3. Biogenerics also takes advantage of special situations and merchant banking opportunities and
makes investments in other public companies in a variety of sectors, including oil and gas, mineral
resources and precious metals.
4. They exist to grow sustainable companies out of great ideas. They take leadership positions in the
companies in which they invest, and provide them with financial and personnel resources, as well as
strategic counsel, in order to help the companies mature into successful commercial enterprises.
The businesses in which they invest are, by their nature, at the leading edge of innovation in their respective fields. It is within their ability to identify and help grow these budding ventures and new technologies that creates increasing value for Biogenerics shareholders.
Biogenerics strategically invests in early stage technology companies, generic pharmaceutical and biotechnology firms that possess true intellectual property. Their focus is on Application and Platform Software, Telecommunications and Fiber Optics, Biomedical Technology companies, as well as other emerging technology environmentally sensitive product areas. Where possible, they look for potential synergies between new companies and those already existing in their portfolio.
The fundamental element underlying all of their pursuits is a forward-looking idea that has application today, along with leadership that has a passion to drive the business forward. They invest in a company's idea, vision, and passion, and take a long-term perspective in growing these organizations into significant commercial enterprises. They act as a catalyst for success by committing both financial and human resources to our investees. As they build superior products, we work with them to build sustainable companies. Our goal is to maximize investment value in the short-term and enhance shareholders' equity in the long-term. Biogenerics also takes advantage of special situations and merchant banking opportunities and makes investments in other public companies in a variety of sectors, including
oil and gas, mineral resources and precious metals.
They exist to grow sustainable companies out of great ideas. They take leadership positions in the companies in which they invest, and provide them with financial and personnel resources, as well as strategic counsel, in order to help the companies mature into successful commercial enterprises.
At Biogenerics Limited., everything they do contributes to the fulfillment of a dream. They are a diversified investment venture capital firm and their shares trade on (NQB: BIGN); their principal business is to fund emerging growth businesses with breakthrough proprietary products.
CORPORATE OFFICERS
Gary Kelley (Chairman of the Board, President & Chief Executive Officer)
Paul Smith (Executive Vice President & Chief Financial Officer)
PRESS ARCHIVE
2004-10-12 - Biogenerics Purchases Interest in North
2004-09-27 - Biogenerics Limited welcomes Paul Smith
2004-08-25 - Biogenerics Limited and Mariners Choice
2004-10-12 - Biogenerics Purchases Interest in North
TORONTO, ONTARIO October 13, 2004 Biogenerics Limited, (NASDAQ PKS: BIGN) is pleased to announce that it has made an investment in 2018251 Ontario Inc., a holding company with significant oil and gas reserves in Ontario, Canada. As part of the longer-term investment plan, Biogenerics intends to purchase a greater interest in 2018251 Ontario Inc., with a first right of refusal, in the productive acreage owned by 2018251 Ontario Inc.
2018251 Ontario Inc. owns several thousand gross acres of off-shore crown land near Romney Township in Kent County and also in the Dover field in Lambton County, Ontario. One of the more important assets of 2018251 Ontario Inc. is an over-riding royalty interest in a five-kilometer long horizontal well in Romney, Ontario, which is the longest horizontal well in North America, and also the recently drilled lateral to this well.
"The existing infrastructure of 2018251 Ontario Inc. offers a unique opportunity for us to complement our existing oil and gas interests in the world, while optimizing the value of our North American interests," said Gary Kelley, President and Chief Executive Officer. "We hope that our long-term investment in this company will lead to other investments in Ontario and especially into investments in new oil and gas recovery technologies like horizontal drilling."
NEED FUNDING PARTNER WITH BIOGENERICS
A company can be created based on ideas, but it's built on management, vision and execution. With their team's depth of experience in strategic planning, team-building, acquisitions, negotiation, operations and financing, they'll work with you on the big picture, so your team can focus more on critical day-to-day operations.
They're not passive partners, nor are they invasive. Their strategic partners attest to their success in building great relationships.
Beginning with a great idea, a sense of chemistry and a congruence of goals, together they're company builders, committed to sustainability over the long term.
Some great ideas just happen. Great companies never do.
They invest in two things: People and true Intellectual Property. With these two components in place, they can help you build your company.
They make decisions quickly and act on them quickly.
When they receive a business plan, they review it, and if they share your vision, they'll contact you to arrange a meeting to discuss the plan in detail and get to know each of your team members. If they reach a sense of business and personal synergy over a few meetings, they'll discuss the terms of investment, and produce a draft term sheet. They like simple structures that are fair to all parties concerned.
They then perform due diligence, evaluating the market, the products or services, the competition and the strategy, in order to develop an in-depth understanding of the business dynamics. They'll check references, and talk to customers and other industry sources.
In parallel with due diligence, they'll start the legal process, and unless significant problems arise, they'll finalize the terms of investment - often within 30 to 60 days of our first meeting.
They want to be the first professional money to invest in your company, and typically take a 20-40% equity stake. This gives them significant influence, but not control, in the company. They usually want a seat on the Board, and full access to company records and information. They're non-invasive, but they're not passive money partners. A good sense of chemistry between Biogenerics and their prospective investees is a crucial factor in whether or not they become partners.
-----------------------------------------------------------------
Disclaimer
This profile published by OTC Live, Inc is an independent electronic publication providing information and factual analysis on selected companies. All statements and expressions are the opinion of OTC Live, Inc and are not meant to be either investment advice or a solicitation or recommendation to buy, sell, or hold securities. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. OTC Live, Inc is not a registered investment advisor or a broker dealer. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Profiles rely on information provided by the featured Companies and/or Edgar filings. While OTC Live, Inc believes its sources to be reliable, associates of OTC Live, Inc,
or any affiliated parties make no representation or warranty as to the accuracy of the information provided. Readers should not rely solely on the information contained in this publication, but should consult with their own independent tax, business and financial advisors with respect to any investment opportunity, including any contemplated investment in the advertised Company.
Factual statements in this publication are made as of the date stated and are subject to change without notice. OTC Live, Inc is not responsible for any claims made by the Company. We have prepared this report, drawing upon a range of public news, the company's website and information from sources in the industry, as well as data and opinions provided by the company. Prior to issuing this report, the Company reviewed and approved the contents in writing hereof. OTC Live, Inc has not independently verified the Company's representations. Any opinions expressed in this report are statements of judgment as of the date of publication. We urge readers to carefully verify all presentations within the report independently. The receipt of this publication shall not create, under any circumstances, any
implication that there has been no change in the affairs of the company profiled since the date of review. This advertisement does not provide an analysis of the Company's financial position. OTC Live, Inc of this advertisement has been compensated twenty thousand free trading registered shares by a third party for the preparation and electronic dissemination of this report and IR services. This should be viewed as a potential conflict of interest. Furthermore, associates of OTC Live, Inc may have stock positions on profiled companies from time to time. We may profit in the event the shares of the Company profiled by us increase in value. These positions may be liquidated from time to time even after we have made positive comments regarding the Company. The receipt of this information constitutes
your acceptance of these terms and conditions.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS: Except for historical information contained herein, the statements on this website and newsletter are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results in the future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition and risk inherent in the companies operations. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ``anticipate,'' ``estimate,'' ``expect,''
``project,'' ``intend,'' ``plan,", "anticipate", "guess", "think", "hear", "suggest", ``believe,'' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance.
As a suggestion, "Never, ever, make an investment based solely on what you read in an online newsletter or Internet bulletin board, especially if the investment involves a small, thinly-traded company that isn't well known," said Nancy M. Smith, Director of SEC's Office of Investor Education and Assistance. "Assume that the information about these companies is not trustworthy unless you can prove otherwise through your own independent research." "Internet Fraud" is available on the SEC's Web Site, at sec.gov.
Subscription Information
Follow the links below for subscription information. To be removed from future mailing, please click on the unsubscribe link.
Subscription Email: -i-shoot-spammers--subscr...@zinester.com
Subscription URL: zinester.com
Unsubscription Email: -i-shoot-spammers--unsubscr...@zinester.com
Unsubscription URL: zinester.com
-----end of forwarded message-----
--
Abuse desk, Institute of Biotechnology, University of Helsinki
P.O. Box 56, FIN-00014 UNIVERSITY OF HELSINKI, FINLAND
Tel. +358-9-1911 (central exchange), biocenter.helsinki.fi/bi/
--
All postings to news.admin.net-abuse.sightings are unconfirmed and
unverified unless stated otherwise by the moderators. All opinions
expressed above are considered the opinions of the original poster,
not the moderators or their respective employers.
For a copy of the guidelines to this group, see:
<URL:http://www.killfile.org/~tskirvin/nana/> |
